Humatrope

Humatrope is a recombinant DNA derived, synthetic form of human growth hormone (hGH) that is used in the treatment of various health conditions. It is produced by Eli Lilly and Company, a global pharmaceutical company.

History[edit | edit source]

Humatrope was first approved by the Food and Drug Administration (FDA) in the United States in 1987. It was one of the first synthetic forms of human growth hormone to be developed and has since been used in the treatment of several conditions related to growth hormone deficiency.

Medical Uses[edit | edit source]

Humatrope is primarily used in the treatment of growth hormone deficiency in both children and adults. In children, this can result in short stature and delayed growth and development. In adults, growth hormone deficiency can lead to changes in body composition, such as increased fat and decreased muscle mass, and decreased bone density.

Humatrope is also used in the treatment of Turner syndrome, a genetic condition that affects growth and development in girls, and chronic kidney disease. It can also be used in children born small for gestational age (SGA) who fail to catch up in growth by age 2-4 years.

Side Effects[edit | edit source]

Like all medicines, Humatrope can cause side effects, although not everybody gets them. Some of the most common side effects include injection site reactions, headaches, fluid retention, and joint pain. More serious side effects can include high blood sugar levels and increased pressure in the brain.

Administration[edit | edit source]

Humatrope is administered through subcutaneous injection. The dosage is determined by the treating physician and is based on the patient's weight, height, and the condition being treated.